Eli Lilly heads into its third-quarter report with a peculiar expectations gap. The published consensus calls for a quarter that looks softer than the last one on paper, yet the stock is near its highs and the unofficial bar sits far above the official one. Management told investors in July that the second half would slow in dollar terms, and the question now is whether the catalysts it described as inflection points arrived quickly enough to make that warning look conservative.
Analysts expect earnings of $7.11 per share on revenue of about $22.11 billion, which would be a 25.6% revenue increase from the $17.60 billion Lilly posted a year ago. That is still exceptional growth for a company of this size, but it marks a clear step down from the 48% pace of the second quarter and implies sales slipping from the $22.97 billion reported last time. The Earnings Whisper of $8.71 is roughly 22% above consensus and even edges past the prior quarter's $8.38, a meaningful gap that suggests the market expects Lilly to blow through the official estimate rather than merely clear it.
The guidance backdrop explains both the confidence and the caution. Lilly has raised its 2026 revenue outlook at each of the last three reports, most recently to $85 billion to $87 billion, and the Street's $85.8 billion sits comfortably inside that range, just under the midpoint. On earnings, the picture is muddier. The top of the per-share range was trimmed to $36.50 even though the underlying midpoint excluding acquired research charges rose sharply, reflecting a busy deal calendar that included Curevo, Limmatech and atai/Beckley. Consensus of $35.34 sits slightly below the low end of the $35.50 to $36.50 range, which hints that analysts are bracing for further acquisition-related charges that could distort the headline number.
Operationally, this is the first quarter that captures the Medicare GLP-1 Bridge Program from day one. Launched July 1, it extended coverage to about 35% more Americans at $50 a month, and management framed it as an inflection. Volume data showing US obesity prescriptions sustaining or improving on the 78% growth seen last quarter would validate that claim. Equally important is the US Foundeo launch, which management admitted ramped more slowly than hoped before turning higher in late July. Prescribers jumped from roughly 8,000 to 36,000 between calls; a further meaningful step up would confirm the late-July turn was real rather than a brief bump. Early international uptake in the UAE, Saudi Arabia and Mexico offers a secondary read.
The risks are known but still matter. US pricing fell about 9% excluding adjustments last quarter, and the second quarter benefited from a one-time rebate estimate change that will not repeat. European seasonality and the lapping of last year's international Monjaro launch should weigh on growth, while Novo's oral product and generic semaglutide in India and Brazil test Lilly's roughly 55% international incretin share. Margins are the cleanest tell: gross margin hit 86.3% and the performance margin reached 54.8%, well above the raised full-year target of 49% to 50.5%. Holding near those levels without the rebate benefit would argue the target is still too low.
Sentiment has improved markedly, with the bearish reading easing to about 10% from roughly 38% before the last report. The stock has gained 9.3% since July while the S&P 500 slipped, and at $1,283.66 it trades about 2% below its post-earnings high of $1,311.75 and well above its 200-day average. That is a stock testing a breakout with expectations already elevated. The deciding factor is whether volume growth from Medicare access and Foundeo outruns price erosion and international comparisons strongly enough to justify a fourth straight guidance raise. Anything short of that may look like a pause in a story priced for acceleration.